• Murat Akova, Ankara, Turkey
  • Maiken Arendrup, Copenhagen, Denmark
  • Sujata Bhavnani, Schenectady, NY, United States
  • Marco Cavaleri, London, United Kingdom
  • Herman Goossens, Edegem, Belgium
  • David Hooper, Boston, MA, United States
  • William Hope, Liverpool, United Kingdom
  • John Rex, Wellesley, MA, United States
  • Jesús Rodríguez Baño, Seville, Spain
  • Keith Rodvold, Chicago, IL, United States
  • Michael Sharland, London, United Kingdom
  • Judith Steenbergen, Boston, MA, United States
  • Sumathi Nambiar, Washington D.C., United States
Antimicrobial drug resistance remains a pressing public health problem. There has been a resurgence in interest in tackling AMR. This conference focusses on the development of new antimicrobial agents for AMR. It is a multidisciplinary meeting that involves basic scientists, clinical academics, regulatory bodies, funding bodies and the pharmaceutical industry. Its scope stretches from chemistry to clinical development, from neonates to adults, from bacteria to fungi – all with a global perspective. The meeting is practical, interactive with plenty of time for networking. We will happily accept original data for poster and platform presentations. We are also especially interested in supporting young investigators and researchers from low to middle income countries.

Drug development for AMR is a rapidly moving field. The stakes are high. A difficult riskbenefit balance must be struck. There are relatively few new classes of antibiotics and each requires highly skilled and experienced investigators to ensure these compounds reach patients. This meeting is the forum where those issues are discussed and debated.

Contact Person (Scientific Programme)

Administrative Secretariat

Venue Info

Event Map
Venue Details
Intercontinental Lisbon
R. Castilho 149, 1099-024 Lisbon

Bootcamps (roundtable discussion and interaction):
  • Medicinal chemistry
  • Preclinical toxicology
  • Preparing for the black swans of resistance
  • Stewardship of new and last resort antibiotics in LMICs – balancing access and control?
State-of-the-art minilectures:
  • Clinical trial design, clinical endpoints, recruitment issues for clinical trials in AMR
  • Metallobetalactamases (epidemiology, drug design, diagnosis and treatment)
  • Pharmacokinetics-Pharmacodynamics
  • Regulatory roundtable
  • New antibacterial agents
  • Approaches to tackle AMR in low to middle income countries
  • Rapid diagnostic testing for AMR
  • Pharmacodynamics of adjunctive therapies: paradigm changing therapies
  • Antifungal agents and antifungal drug development
  • Drug discovery in academia
  • Breakpoints for new antimicrobial agents
  • Clinical trial design for AMR
More detailed information will be available shortly.
If you are an ASM member, please kindly send the membership proof to lisbon2018@escmid.org in order to be given the membership discount.
No certificate found
Share and discuss your research with colleagues from around the world. Abstracts can be submitted from 1 March - 22 June 2018.
Please download the template and submit it by email to: lisbon2018@escmid.org
If you have any questions or need any assistance, please do not hesitate to contact us at lisbon2018@escmid.org

For more detailed information, please download the flyer HERE and the poster HERE.